NORTH AMERICA IMMUNOGLOBULIN MARKET FORECAST 2022-2030

TABLE OF CONTENTS

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. KEY DRIVERS

3.1.1. GROWTH IN GERIATRIC POPULATION

3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

3.2. KEY RESTRAINTS

3.2.1. HIGH COST OF THERAPY

3.2.2. HIGH RISK OF SIDE EFFECTS

4.     KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET

4.2. KEY MARKET TRENDS

4.3. PORTER’S FIVE FORCES ANALYSIS

4.3.1. BUYERS POWER

4.3.2. SUPPLIERS POWER

4.3.3. SUBSTITUTION

4.3.4. NEW ENTRANTS

4.3.5. INDUSTRY RIVALRY

4.4. OPPORTUNITY MATRIX

4.5. VENDOR LANDSCAPE

4.6. KEY BUYING CRITERIA

4.6.1. SOURCE

4.6.2. APPLICATION

4.6.3. EPITOPE

4.6.4. VALIDATION

4.7. REGULATORY FRAMEWORK

5.     MARKET BY PRODUCT

5.1. IGG

5.2. IGA

5.3. IGM

5.4. IGE

5.5. IGD

6.     MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN

6.2. SUBCUTANEOUS IMMUNOGLOBULIN

6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7.     MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA

7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

7.3. PRIMARY IMMUNODEFICIENCY DISEASES

7.4. MYASTHENIA GRAVIS

7.5. MULTIFOCAL MOTOR NEUROPATHY

7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

7.7. INFLAMMATORY MYOPATHIES

7.8. SPECIFIC ANTIBODY DEFICIENCY

7.9. GUILLAIN-BARRE SYNDROME

7.10. OTHER APPLICATIONS

8.     MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY

8.2. SPECIALTY PHARMACY

8.3. OTHER DISTRIBUTION CHANNELS

9.     MARKET BY END-USER

9.1. HOSPITALS & CLINICS

9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA

10.1.1. MARKET SIZE & ESTIMATES

10.1.2. KEY GROWTH ENABLERS

10.1.3. KEY CHALLENGES

10.1.4. KEY PLAYERS

10.1.5. COUNTRY ANALYSIS

10.1.5.1.    UNITED STATES

10.1.5.2.    CANADA

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS

11.1.1. MERGERS & ACQUISITIONS

11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS

11.1.3. PARTNERSHIPS & AGREEMENTS

11.1.4. BUSINESS EXPANSIONS & DIVESTITURES

11.2. COMPANY PROFILES

11.2.1. ADMA BIOLOGICS

11.2.2. BIO PRODUCTS LABORATORY

11.2.3. BIOTEST AG

11.2.4. CHINA BIOLOGIC PRODUCTS INC

11.2.5. CSL BEHRING

11.2.6. GRIFOLS SA

11.2.7. KAMADA LTD

11.2.8. KEDRION BIOPHARMA

11.2.9. LFB GROUP

11.2.10. OCTAPHARMA AG

11.2.11. PFIZER INC

11.2.12. SANQUIN PLASMA PRODUCTS BV

11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED

 

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 5: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 7: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 15: LEADING PLAYERS OPERATING IN NORTH AMERICA IMMUNOGLOBULIN MARKET

TABLE 16: LIST OF MERGERS & ACQUISITIONS

TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 19: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

 

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 7: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

FIGURE 8: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

FIGURE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

FIGURE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

FIGURE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

FIGURE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 15: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 16: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 17: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

FIGURE 18: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 19: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 20: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

FIGURE 21: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 22: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

FIGURE 23: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

FIGURE 24: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 25: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

FIGURE 26: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 27: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 28: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 29: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 30: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

FIGURE 31: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 32: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 33: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

FIGURE 34: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: UNITED STATES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: CANADA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

The North America immunoglobulin market is predicted to record a CAGR of 6.95% during the forecasted period of 2022 to 2030. The market growth of the region is propelled by major factors such as the high incidence of various diseases, the presence of key industry players, and the growth in product approvals by the United States Food and Drug Administration (FDA).

 

Get more Insights into the North America Immunoglobulin Market:

https://inkwoodresearch.com/reports/north-america-immunoglobulin-market/

 

MARKET INSIGHTS

The North America immunoglobulin market growth assessment covers the evaluation of Canada and the United States. In Canada, intravenous immunoglobulin is primarily distributed by the Canadian Blood System to the country’s blood banks within hospital settings. Subsequently, hospital blood banks then dispense intravenous immunoglobulin to individual patients as prescribed. In addition, various institutions also maintain a comprehensive database inventory regarding the usage of the same. Intravenous immunoglobulin is licensed by Health Canada for the treatment of secondary and primary immune deficiencies, allogeneic bone marrow transplantation, idiopathic thrombocytopenic purpura, Kawasaki disease, chronic B-cell lymphocytic leukemia, as well as pediatric HIV-infection.

Over recent years, Canada has also recorded significant infrastructural development associated with immunoglobulin and plasma. This factor is set to have a positive impact on the country’s market growth. Aligning with this, in 2019, Canadian Blood Services announced its proposition to open plasma donation sites across three provinces in order to secure the supply for patients. As a result, these factors are expected to supplement the growth of the immunoglobulin market in North America during the forecast period.

 

COMPETITIVE INSIGHTS

Top players operating in the market include ADMA Biologics, Pfizer Inc, CSL Behring, etc.

 

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation cater to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.     ADMA BIOLOGICS

2.     BIO PRODUCTS LABORATORY

3.     BIOTEST AG

4.     CHINA BIOLOGIC PRODUCTS INC

5.     CSL BEHRING

6.     GRIFOLS SA

7.     KAMADA LTD

8.     KEDRION BIOPHARMA

9.     LFB GROUP

10. OCTAPHARMA AG

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. TAKEDA PHARMACEUTICAL COMPANY LIMITED